文献速递炎症性肠病

克罗恩病合并化脓性汗腺炎与永久性造口风险增加相关:一项病例对照研究

Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-11

这项回顾性病例对照研究纳入2003至2016年Saint-Antoine医院消化内科转诊的4645例克罗恩病患者,比较合并与未合并化脓性汗腺炎者的临床特征与预后。化脓性汗腺炎患病率为0.95%(44例),80%为Hurley II或III期。合并化脓性汗腺炎者疾病更活动、抗TNF药物使用更多,永久性造口风险更高,多因素分析证实化脓性汗腺炎为永久性造口的独立危险因素(OR 6.19;95%CI 2.30-38.33;P<0.001)。

要点

  • 克罗恩病患者中化脓性汗腺炎患病率为0.95%(44例),80%为Hurley II或III期。
  • 合并化脓性汗腺炎者活动期年比例为56% vs 40%(P<0.001),抗TNF治疗年比例为39% vs 23%(P<0.001)。
  • 合并化脓性汗腺炎者永久性造口风险为16.8%(IQR 7.5-33.3)vs 对照组2.5%(IQR 0.8-7.4),P=0.002。

核心结论

  • 化脓性汗腺炎与更差的克罗恩病预后相关,包括疾病更活动和永久性造口风险增加,尽管抗TNF药物使用更多。

研究设计与样本

  • 回顾性病例对照研究,纳入2003至2016年Saint-Antoine医院消化内科三级诊疗中心转诊的4645例克罗恩病患者。
  • 匹配变量为性别、年龄、克罗恩病诊断时年龄及肛周病变 presence、随访质量。
  • 化脓性汗腺炎经皮肤科检查确认,记录部位、表型和严重程度(Hurley分期)。

主要发现

  • 化脓性汗腺炎患病率为0.95%(44例),80%患者为Hurley II或III期。
  • 70%病例中克罗恩病先于化脓性汗腺炎出现,中位间隔9年(IQR 5.25-12.75)。
  • 合并化脓性汗腺炎者活动期年比例为56% vs 40%(P<0.001),抗TNF治疗年比例为39% vs 23%(P<0.001)。
  • 合并化脓性汗腺炎者永久性造口风险为16.8%(IQR 7.5-33.3)vs 对照组2.5%(IQR 0.8-7.4)(P=0.002)。
  • 多因素分析证实化脓性汗腺炎为永久性造口的独立危险因素(OR 6.19;95%CI 2.30-38.33;P<0.001)。

关键数值与推荐

  • 化脓性汗腺炎严重程度采用Hurley分期,80%患者为II或III期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Crohn's disease (CD) and hidradenitis suppurativa (HS), a chronic inflammatory skin disease, induce similar inflammatory lesions of the groin and gluteal area. Both diseases are characterised by an inadequate immune response to commensal bacteria in genetically predisposed subjects and can be associated. AIM: To assess whether HS was associated with clinical and prognostic factors in CD. METHODS: A retrospective case-control study included 4645 patients with CD referred to Saint-Antoine Hospital gastroenterology tertiary care centre between 2003 and 2016. Matching variables were sex, age, age and the presence of perianal lesions at CD diagnosis, follow-up quality. HS was confirmed by dermatological examination; location, phenotype and severity (Hurley staging) were recorded. RESULTS: Hidradenitis suppurativa prevalence was 0.95% (44 cases); 80% of patients displayed Hurley stage II or III disease. CD preceded HS in 70% of cases with a median interval of 9 years (IQR 5.25-12.75). CD with HS was more active (56% vs 40% years with active disease, P < 0.001) and required more anti-TNF agents (39% vs 23% years spent with anti-TNF treatment, P < 0.001) than CD without HS. HS was associated with a higher risk of permanent stoma, 16.8% (IQR 7.5-33.3) vs 2.5% (IQR 0.8-7.4) in the control group (P = 0.002). Multivariate analysis confirmed HS as independent risk factor for permanent stoma (odds ratio 6.19; 95% CI, 2.30-38.33; P < 0.001). CONCLUSIONS: Hidradenitis suppurativa is associated with worse CD prognosis, more active disease and increased risk of permanent stoma, despite a higher use of anti-TNF agents.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dumont LM, Landman C, Sokol H, et al. Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study. Aliment Pharmacol Ther. 2020. PMID: 32525586. doi:10.1111/apt.15863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。